Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04522544 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Study acronym: IMMUWIN
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 12 to 11
    v7
  2. Primary completion date: Dec 31, 2025 to Jul 31, 2027
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v6
  3. Primary completion date: Mar 31, 2025 to Dec 31, 2025v5 Show 4 more changesShow less
    • Study sites: 9 to 12
    • Study completion date: Sep 30, 2025 to Dec 31, 2026
    • Study description shortened, about 43 words
    • Study title shortened, about 3 words
  4. Enrollment target: 84 to 55v4 Show 8 more changesShow less
    • Primary completion date: Mar 31, 2024 to Mar 31, 2025
    • Study sites: 2 to 9
    • Study completion date: Sep 30, 2024 to Sep 30, 2025
    • Interventions: Durvalumab (Drug), TACE (Procedure), Tremelimumab (Drug), Y-90 SIRT (Procedure) to DEB-TACE (Procedure), Durvalumab (Drug), Tremelimumab (Drug), Y-90 SIRT (Procedure)
    • Study description revised
    • Collaborators: 1 to 2
    • Eligibility criteria expanded, about 1 word
    • Study title shortened, about 4 words
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Sep 30, 2020 to Dec 15, 2020
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Trial Details
NCT Number NCT04522544
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: AstraZeneca, Hannover Medical School
Conditions
(from sponsor)		 Hepatocellular Carcinoma Non-resectable, HCC
Related terms Carcinoma, Hepatocellular
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov